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Serious neonatal morbidities are associated
with differences in DNA methylation
among very preterm infants
Todd M. Everson1* , T. Michael O’Shea2, Amber Burt1, Karen Hermetz1, Brian S. Carter3, Jennifer Helderman4,
Julie A. Hofheimer2, Elisabeth C. McGowan5, Charles R. Neal6, Steven L. Pastyrnak7, Lynne M. Smith8,
Antoine Soliman9, Sheri A. DellaGrotta10, Lynne M. Dansereau10, James F. Padbury5, Barry M. Lester5,10,11
and Carmen J. Marsit1

Abstract
Background: Infants born very preterm are more likely to experience neonatal morbidities compared to their term
peers. Variations in DNA methylation (DNAm) associated with these morbidities may yield novel information about
the processes impacted by these morbidities.
Methods: This study included 532 infants born < 30 weeks gestation, participating in the Neonatal Neurobehavior
and Outcomes in Very Preterm Infants study. We used a neonatal morbidity risk score, which was an additive index of
the number of morbidities experienced during the NICU stay, including bronchopulmonary dysplasia (BPD), severe
brain injury, serious neonatal infections, and severe retinopathy of prematurity. DNA was collected from buccal cells
at discharge from the NICU, and DNAm was measured using the Illumina MethylationEPIC. We tested for differential
methylation in association with the neonatal morbidity risk score then tested for differentially methylated regions
(DMRs) and overrepresentation of biological pathways.
Results: We identified ten differentially methylated CpGs (α Bonferroni-adjusted for 706,278 tests) that were associated with increasing neonatal morbidity risk scores at three intergenic regions and at HPS4, SRRD, FGFR1OP, TNS3,
TMEM266, LRRC3B, ZNF780A, and TENM2. These mostly followed dose–response patterns, for 8 CpGs increasing DNAm
associated with increased numbers of morbidities, while for 2 CpGs the risk score was associated with decreasing
DNAm. BPD was the most substantial contributor to differential methylation. We also identified seven potential DMRs
and over-representation of genes involved in Wnt signaling; however, these results were not significant after Bonferroni adjustment for multiple testing.
Conclusions: Neonatal DNAm, within genes involved in fibroblast growth factor activities, cellular invasion and
migration, and neuronal signaling and development, are sensitive to the neonatal health complications of prematurity. We hypothesize that these epigenetic features may be representative of an integrated marker of neonatal health
and development and are promising candidates to integrate with clinical information for studying developmental
impairments in childhood.
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Introduction
Much progress has been made in reducing neonatal
morbidity and mortality among infants who are born
very preterm (< 30 weeks of gestation). However, these
neonates remain at risk for multiple serious medical
complications, which often require extended stays in
the neonatal intensive care unit (NICU). These include
bronchopulmonary dysplasia (BPD), severe brain injury
(SBI), severe retinopathy of prematurity (ROP) and serious neonatal infections (INF). Even after recovering
from these potentially serious health complications and
being discharged from the NICU, these infants are at
increased risk of having long-term neurodevelopmental
impairments.
Schmidt et al. [1] showed that BPD, SBI, and severe
ROP were each independently associated with poor
18-month outcomes, including cerebral palsy, cognitive delay, hearing loss, blindness, or death; importantly,
they also showed that the additive accumulation of these
morbidities was a strong predictor of impairment or
death. Necrotizing enterocolitis (NEC), a severe gastrointestinal infection associated with prematurity, has also
been identified as a predictor of developmental impairments in childhood [2]. The inclusion of neonatal infections and NEC into a cumulative neonatal morbidity
risk score, along with BPD, SBI and ROP, improves the
ability to predict impairment or death by 18 months of
age [3]. These severe neonatal morbidities frequently cooccur among premature infants and have some shared
risk factors and pathophysiology. For instance, preterm
infants with severe BPD are more likely to have severe
ROP compared to infants without BPD [4], and both of
these health complications may be influenced by altered
regulation of angiogenic and/or angiostatic factors [5].
Additionally, severe ROP tends to occur in infants that
have brain injury and impaired mental and psychomotor development [6], which may be partly due to prenatal and neonatal infections and prolonged inflammatory
responses [7, 8].
We hypothesized that these neonatal morbidities may
be related to underlying differences in developmental
regulation or disruptions of other biological processes,
which may be encoded in DNA methylation (DNAm).
DNAm is an epigenetic mechanism for regulating gene
expression potential that is not due to alterations in the
DNA sequence, which can be heritable across cellular
divisions, and typically occur at cytosine-phosphate-guanine (CpG) motifs. Infants who are born preterm have

different DNAm patterns when compared to term infants
[9–12] and some of these differences appear to persist
into adulthood [9, 12]. Additionally, in preterm infants
alterations in DNAm have been associated with sepsis
[13], pain-related stress [14, 15], a potential moderator
of serotonergic tone and temperament [16], and neurobehavioral responses [17]. Thus, variations in neonatal
DNAm may serve as a blueprint linking preterm birth,
the health complications that these infants experience,
and some of the persistent developmental impairments
for which they are at heightened risk.
In this study, we examined the relationships between
the cumulative impact of serious neonatal morbidities experienced during NICU stay, including BPD, SBI,
INF, and severe ROP, on DNAm measured at NICU discharge; we focus on this set of serious health complications because these are also risk factors for persistent
impairments later in childhood [1, 3]. We hypothesize
that even after these neonatal morbidities have resolved,
infants likely have varying degrees of prematurity and
impairment which may be reflected in their epigenetic
profiles, and since prematurity has systemic effects on
multiple organ systems throughout the body, this can
be detected in peripheral tissues. The identification of
an epigenetic signal that associates with the cumulative impact of multiple neonatal morbidities can provide
unique insights into the processes that either contribute
to, or are affected by, these severe health complications.
We performed this analysis within the ongoing Neonatal
Neurobehavior and Outcomes in Very Preterm Infants
(NOVI) Study. Our long-term aims are to test whether
integrating these epigenetic data with clinical data can
improve the focus of interventions on infants at highest
risk for persistent neurodevelopmental impairments later
in childhood.

Materials and methods
Study population

The Neonatal Neurobehavior and Outcomes in Very Preterm Infants (NOVI) Study was conducted at nine university-affiliated NICUs from April 2014 through June
2016 who were also Vermont Oxford Network (VON)
participants. All participating mothers provided written
informed consent. Enrollment and consent procedures
for this study were approved by local institutional review
boards. Inclusion criteria included: (1) birth at < 30 weeks
gestational age; (2) parental ability to read and speak
English or Spanish; and (3) residence within 3 h of the
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NICU and follow-up clinic. Gestation estimates to determine birth < 30 weeks gestational age were based on the
Extremely Low Gestational Age Newborns (ELGAN)
Study criteria [18, 19]. Exclusion criteria included
maternal age < 18 years, maternal cognitive impairment, infants with major congenital anomalies, maternal death, or infant death in the NICU [20, 21]. Parents
of eligible infants were invited to participate in the study
when infant survival was deemed likely by the attending
neonatologist.
Maternal interviews were performed to collect demographic information such as age, race and ethnicity, and
educational attainment, while the Hollingshead Index
was used to assess socioeconomic status (SES) with a
Hollingshead level V indicating low SES [22]. Infant
medical records were reviewed to collect birthweight,
gestational age, length of NICU stay, whether the newborn was outborn, and diagnoses of neonatal morbidities
described in detail below. Outborn refers to infants that
were born in a hospital without subspecialty providers
of neonatal intensive care and were transferred, almost
always on the day of birth, to a tertiary center for subspecialty care. Gestational age was estimated using the highest quality of available information: first using the dates of
embryo retrieval or intrauterine insemination, then using
fetal ultrasound, then using date of last menstrual period
(LMP), and finally assigned by attending neonatologist in
the absence of the above information. Postmenstrual age
(PMA) is used to describe the age preterm infants during their time in the NICU and is defined as the combination of gestational age at birth plus the length of NICU
stay. Buccal cells were collected for epigenomic analyses
during the week of discharge from the NICU (± 3 days);
thus, PMA at buccal swab collection represents the combination of gestational age at birth plus the length of
NICU stay (± 3 days). Overall, 704 infants were enrolled
and buccal cells were collected on 624 of these infants for
epigenomic screening.
NICU neonatal morbidities

Trained personnel at each site reviewed medical records
and used Vermont-Oxford Network (VON) definitions
and criteria [20] to collect information about infections,
grades of ROP, and neonatal BPD through the time of
discharge from the NICU. Infections included sepsis,
defined as recovery of a bacterial pathogen from blood
culture, and NEC, defined as having one or more of the
following clinical signs: bilious gastric aspirate or emesis,
abdominal distention, and occult or gross blood in stool
not attributable to an anal fissure and one or more of the
following radiographic signs: pneumatosis intestinalis,
hepato-biliary gas, and pneumoperitoneum. Bronchopulmonary dysplasia (BPD) is one of the most common and
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serious forms of chronic lung disease among preterm
infants, which is defined by the level of respiratory assistance required at 36 weeks PMA and can be categorized
into different levels of severity (mild/moderate/severe)
[23]. BPD was defined as requiring supplemental oxygen at 36 weeks PMA. For this study, any BPD regardless
of severity was included in the neonatal morbidity risk
score. Ascertainment of severe brain injury was based
on cranial ultrasounds. When available, two ultrasound
examinations were considered for each study participant;
an “early” ultrasound, typically performed within a week
of postnatal day 7, and a “late” ultrasound, typically performed between 36 weeks PMA and discharge. Criteria
for SBI were similar to those used by Bassler et al. [3]
and included parenchymal echodensity (PED), periventricular leukomalacia (PVL), and moderate to severe ventricular dilation (VDIL) with or without intraventricular
hemorrhage.
Cranial ultrasounds were performed using high-frequency transducers with six standard quasi-coronal
views and five para-sagittal views. Ultrasounds were read
initially as part of routine clinical care and were read subsequently by a NOVI Study neuro-radiologist who classified observations according to criteria developed for
the Extremely Low Gestational Age Newborn (ELGAN)
study [24]. A third reading, by a NOVI Study neuroradiologist, was performed if there was disagreement
between the initial and the second readings, regarding
the presence of one or more of the following: PED, PVL,
or moderate to severe VDIL. Ultrasound abnormalities were classified as present if identified by at least two
readers [25].
We calculated an adaptation of Bassler et al.’s validated
[3] cumulative neonatal morbidity risk score by adding
the number of neonatal health complications, including
BPD, severe ROP, SBI, and culture-confirmed infection
[3] that each infant experienced during their stay in the
NICU. Due to very small numbers of infants experiencing
all four morbidities, we combined those that experienced
three or four morbidities into a single group, resulting in
four possible levels for the risk score of 0, 1, 2, or 3 + .
DNA methylation (DNAm) measurement, quality control,
and preprocessing

DNA extraction was performed with the Isohelix Buccal Swab system (Boca Scientific). DNA was quantified
with the Qubit Fluorometer (Thermo Fisher, Waltham,
MA, USA), then aliquoted into standardized concentrations (~ 500 ng/uL) to allow for a total mass of 500 ng
of DNA to undergo bisulfite modification and array
analysis. The samples were randomly distributed across
96-well plates, rows, and chips to reduce the potential for batch effects. The Emory University Integrated
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Genomics Core performed bisulfite modification using
the EZ DNA Methylation Kit (Zymo Research, Irvine,
CA) and measured DNAm throughout the genome with
the Illumina MethylationEPIC Beadarray (Illumina, San
Diego, CA) following the manufacturer’s protocol. Samples with more than 5% of probes yielding detection p
values > 1.0E−5 (74 samples), with mismatch between
reported and predicted sex (7 samples), or incomplete
covariate data (11 samples) were excluded. Functional
normalization and beta-mixture quantile (BMIQ) normalization were performed [26], then probes on the X
and Y chromosomes, those that had single nucleotide
polymorphisms (SNP) within the binding region, those
that could cross-hybridize to other regions of the genome
[27], or probes that had low variability (range of beta-values < 0.05) [28] were excluded. After exclusions, 706,278
probes were available from 532 samples. The methylation
data are publicly accessible through NCBI Gene Expression Omnibus (GEO) via accession series GSE128821.
Estimates of tissue heterogeneity

We estimated the proportions of epithelial, fibroblast,
and immune cells in our buccal samples using reference
methylomes [29]. As demonstrated in our prior work,
epithelial cells made up 95.7% of the cells in 95% of our
samples, while immune cells made up the majority of the
remaining cell types [30]. The proportions of individual
immune cell subtypes were strongly inversely correlated
with the proportions of epithelial cells, and very few samples had any estimated fibroblasts. Thus, we adjusted for
cellular heterogeneity by including the proportions of
epithelial cells as covariates in our statistical models. We
also performed a sensitivity analysis to test whether the
results were consistent after additionally adjusting for all
immune cell proportions.
Confounding variables

We used a directed acyclic graph (DAG) and supporting literature to demonstrate the potential confounders, cellular heterogeneity, and batch effects that needed
to be adjusted for in our study (Additional file 1: Figure
S1). Others have shown that the neonatal morbidities
included in this risk score are more common among
males [31], those who were outborn [32, 33], and those
with shorter gestation [34, 35]. Similarly, differences in
DNAm have been associated with sex differences [36],
gestational age and preterm birth [37, 38], and outborn
status may capture a number of factors that we hypothesize could contribute to differences in DNA methylation,
including delays in receiving treatment and care [39].
Thus, gestational age, outborn, and sex are traditional
confounders. While samples were randomized across
the array to reduce bias related to batch, we additionally
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adjusted for a categorical batch variable to ensure that
batch effects were adequately controlled for, and it is well
recognized that cellular heterogeneity should be estimated and controlled for in epigenomic studies using
cellular mixtures [29]. In all models, we adjusted for sex,
whether the newborn was outborn (delivery occurred at
a health care facility and then transferred to the NICU
where enrollment in NOVI occurred), gestational age at
birth (in weeks), the proportion of estimated epithelial
cells, recruitment site (6-level factor), and batch (7-level
factor).
Statistical analyses: R packages

All statistical analyses were performed in R version 3.6.1.
Robust linear regressions were carried out using the
MASS package, robust standard errors were estimated
using the sandwich package, and partial residual plots
were produced with the visreg package. Manhattan and
QQ plots were produced with the qqman package, and
inverse-variance weighted fixed effects meta-analyses
were performed with the metafor package.
Statistical analyses: identification of PMA‑associated CpGs

Prior to performing an epigenome-wide association
study (EWAS) to identify the relationships between the
neonatal morbidity risk scores and buccal cell DNAm,
we explored the interrelationships between gestational
age, PMA at buccal swab collection, and the risk score
(Additional file 1: Figure S2). Buccal cell collection was
performed close to NICU discharge and infants with
more health complications typically required longer
stays in the NICU. Thus, cumulative neonatal morbidity risk score and PMA at buccal swab collection are
strongly correlated in our data; additionally, the number of morbidities was inversely correlated with gestational age at birth (Additional file 1: Figure S3). There
is a well-recognized relationship between DNAm and
aging [40], and thus, we were concerned that many of
the CpGs that we identify in association with the neonatal morbidities might solely be associated with neonatal aging metrics rather than the upstream exposure
of the risk score. Gestational age is likely a cause of
both increasing numbers of neonatal health complications and of differential DNAm and is thus a traditional confounder that can be statistically adjusted for
in our models. However, because PMA at buccal swab
collection is a consequence of the exposure and cannot
cause the health complications, it is not a traditional
confounder and including this variable in our all of
our EWAS models may result in over-adjustment [41].
To deal with this issue, we first performed an analysis
aimed at identifying the CpG sites that were associated with PMA at buccal swab collection that were not
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driven by the antecedent neonatal morbidities. To do
this, we stratified our data by level of the neonatal morbidity risk score (those with 0, 1, 2, or 3 + morbidities)
and performed separate EWAS within each of these
strata. DNAm was regressed on PMA at buccal swab
collection, while adjusting for sex, outborn, site, batch,
and epithelial cell proportions; due to the small sample size in the stratum with 3 + complications (n = 28),
site and batch were not included in the models for this
stratum. We then performed inverse-variance weighted
fixed effects meta-analyses to estimate the average
effect of PMA at buccal swab collection on DNAm
across all levels of the neonatal morbidity risk score.
Those CpGs that yielded meta-analysis p values < 0.05
were determined to be potential surrogate markers of
PMA, independent of the neonatal health complications. For these CpGs, weeks of PMA at the time of
buccal cell collection were included as an additional
adjustment covariate in the EWAS for the risk score
described below. CpGs that did not associate with PMA
in the meta-analysis were modeled without including
PMA at buccal swab collection as a covariate to avoid
over-adjustment.
Statistical analyses: epigenome‑wide associations study
(EWAS) for neonatal morbidity risk score

We tested for linear associations between DNAm and
increasing neonatal morbidity risk scores by regressing DNAm (dependent variable) at each CpG site on
the risk score as a continuous variable (range of 0–3),
while adjusting for sex, whether the infant was outborn,
GA at birth (weeks), recruitment site, batch (plate),
and proportions of epithelial cells. Among those CpGs
that were determined to be potential surrogate markers of PMA, weeks of PMA at buccal swab collection
were included as an additional covariate. QQ-plots
and Manhattan plots were produced to summarize the
overall EWAS findings. To account for multiple testing, we implemented a false discovery rate (FDR) of
10% to determine which CpGs should be reported in
the supplemental materials and Bonferroni adjustment
(α = 0.05/706,278) to determine the statistically significant associations from our EWAS. We then examined the associations with risk score as 4-level factor
variable to estimate the average differences in DNAm
associated with each level of the risk score (1, 2, or
3 +) when compared to infants that experienced none
of the neonatal morbidities. To assess whether the factor-level coefficients for differential DNAm increased
in magnitude as the neonatal morbidity risk score
increased, we compared the regression coefficients for
1, 2, or 3 + complications against each other via scatter

Page 5 of 15

plots for all CpGs that were significant at the FDR 10%
threshold.
Statistical analyses: identification of differentially
methylated regions (DMRs)

We then used DMRff to search for differentially methylated regions [42]. Candidate regions were identified by
specifying a maximum distance between individually
differentially methylated CpGs (maxgap) to be 1500 bp
and required a minimum p value (p.cutoff) of at least
0.001 from the EWAS. The dmrff function estimates
regional differential methylation within these candidate
regions using an extension of inverse-variance weighted
meta-analysis on the parameter estimates and standard errors from the EWAS, for those CpGs within the
candidate regions. Regional test-statistics as well as raw
and adjusted p values are calculated, and the adjusted p
values track closely with the EWAS-level Bonferronicorrected p values. Due to the greedy selection through
which candidate regions are identified, an FDR adjustment of the raw DMR p values may be inappropriate.
Thus, we selected all DMRs that produced a regional p
values less than or equal to the largest p value that was
within the 10% FDR threshold, from the CpG-by-CpG
EWAS, to report in the supplemental materials. We considered those DMRs with adjusted p values < 0.05 to be
statistically significant.
Statistical analyses: differential DNAm associated
with individual neonatal morbidities

To examine whether individual health complications
were driving the majority of the epigenetic responses at
these CpGs, we then produced models without the neonatal morbidity risk score, but instead with factor variables for BPD (any versus none), SBI (any versus none),
INF (any versus none), and ROP (any versus none), while
adjusting for the same confounders that were included in
the EWAS; again weeks of PMA at buccal swab collection
was included as a covariate for CpGs that were previously
identified as potential surrogate markers of PMA. For
these analyses, all four morbidities were included in the
same models together, to assess whether DNAm at some
of these CpGs was more affected by specific health complications. We used Venn diagrams to show the relative
contribution of each individual morbidities to differential
methylation at these CpGs and to demonstrate the overlap in statistically significant associations for each health
complication.
Statistical analyses: over‑representation of genes
in biological pathways

To gain insights into the biological functions of the genes
associated with the CpGs we identified, we performed
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over-representation analyses with methylGSA, which
accounts for the number of CpGs annotated to each
gene [43]. We tested for over-representation of biological
pathways among the CpGs that were associated with the
neonatal morbidity risk scores at an FDR of 10%.

at birth and increased PMA at buccal swab collection (p
value < 0.001), while risk scores also differed by recruitment site (p value = 0.001) as well as maternal race and
ethnicity (p value = 0.05) (Table 1).

Results

Infants with more health complications tended to have
longer stays at the NICU and thus had increased PMA at
the time of buccal swab collection and age metrics can
have strong associations with DNAm. Thus, we aimed
to limit the chances of us detecting CpGs that were surrogate markers of PMA at the time of buccal swab collection when we performed an EWAS of the neonatal
morbidity risk score. To do this, we first performed an
EWAS of PMA at buccal cell collection to identify those
CpGs that are associated with aging, independent of
the risk scores. We identified a very substantial epigenetic signal for weeks of PMA at buccal swab collection
with 13,034, 85,837, and 142,580 CpGs being associated

Characteristics of the study population

Infants in the NOVI sample for whom DNAm data and
composite neonatal morbidity risk scores were available
(N = 532), had high prevalence (n = 319, 60.0%) of experiencing at least one of the four neonatal morbidities
(BPD, SBI, INF, or ROP), while a small subset of these
infants experienced three or more of these morbidities
(n = 28, 5.3%) (Table 1). The most common health complication in our sample was BPD (273, 51%), with severe
ROP being least common (34, 6.4%). As expected, infants
with increasing numbers of complications were more
likely to be outborn, tended have shorter gestational ages

Identification of PMA‑associated CpGs

Table 1 Distribution of demographic characteristics, neonatal morbidities and maternal/fetal characteristics of the study
population overall and stratified by composite neonatal morbidity risk scores; ANOVA and χ2 tests were used to assess
differences in characteristics across the levels of risk scores
Sample characteristics (N = 532)

Stratified by Risk Score

Overall

0 (n = 213)

1 (n = 193)

2 (n = 98)

3 + (n = 28)

p value

BPD (%)

273 (51.3)

0 (0.0)

152 (78.8)

94 (95.9)

27 (96.4)

< 0.001

INF (%)

99 (18.6)

0 (0.0)

24 (12.4)

56 (57.1)

19 (67.9)

< 0.001

SBI (%)

68 (12.8)

0 (0.0)

16 (8.3)

31 (31.6)

21 (75.0)

< 0.001

ROP (%)

34 (6.4)

0 (0.0)

1 (0.5)

15 (15.3)

18 (64.3)

< 0.001

GA (weeks)

27.01 (1.92)

27.95 (1.46)

26.92 (1.83)

25.74 (1.85)

24.91 (1.50)

< 0.001

PMA (weeks)

39.08 (3.29)

36.77 (1.87)

39.77 (2.79)

41.97 (3.31)

41.81 (2.77)

< 0.001

68 (12.8)

26 (12.2)

20 (10.4)

19 (19.4)

3 (10.7)

Race and ethnicity (%)
Hispanic other
Hispanic white

0.05
43 (8.1)

13 (6.1)

16 (8.3)

11 (11.2)

3 (10.7)

Non-Hispanic other

180 (33.8)

76 (35.7)

70 (36.3)

29 (29.6)

5 (17.9)

Non-Hispanic white

234 (44.0)

94 (44.1)

86 (44.6)

39 (39.8)

15 (53.6)

7 (1.3)

4 (1.9)

1 (0.5)

0 (0.0)

2 (7.1)

Outborn (%)

112 (21.1)

30 (14.1)

34 (17.6)

37 (37.8)

11 (39.3)

Male (%)

297 (55.8)

130 (61.0)

100 (51.8)

54 (55.1)

13 (46.4)

0.201

29.10 (6.39)

29.13 (6.60)

29.49 (6.02)

28.35 (6.77)

28.95 (5.93)

0.556

Not reported

Maternal age (years)

< 0.001

Education < HS/GED (%)

72 (13.9)

28 (13.7)

21 (11.1)

19 (19.6)

4 (14.8)

0.276

Lowest SES (%)

42 (8.1)

15 (7.4)

15 (7.9)

8 (8.2)

4 (14.8)

0.615

WIH

94 (17.7)

30 (14.1)

47 (24.4)

12 (12.2)

5 (17.9)

SHD

100 (18.8)

52 (24.4)

31 (16.1)

12 (12.2)

5 (17.9)

KMC

88 (16.5)

44 (20.7)

25 (13.0)

15 (15.3)

4 (14.3)

Recruitment site (%)

0.001

CMH

68 (12.8)

16 (7.5)

25 (13.0)

22 (22.4)

5 (17.9)

WFU

113 (21.2)

50 (23.5)

35 (18.1)

21 (21.4)

7 (25.0)

LUB

69 (13.0)

21 (9.9)

30 (15.5)

16 (16.3)

2 (7.1)

BPD bronchopulmonary dysplasia, INF neonatal infection, SBI severe brain injury, ROP severe retinopathy of prematurity, GA gestational age, PMA postmenstrual age,
HS high school, GED general educational development test, SES socioeconomic status
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with PMA at various thresholds of statistical significance: Bonferroni correction, FDR of 10%, and raw p values < 0.05, respectively (Additional file 11 Figure S4). For
the 142,580 CpGs yielding even modest evidence of an
association with PMA, we chose to include PMA in the
EWAS models of neonatal morbidity risk scores. On the
other hand, we were not concerned about DNAm being a
potential surrogate marker of PMA at buccal cell collection for the other 563,698 CpGs, and thus, PMA at buccal
swab collection was not included as a covariate for those
CpGs in the EWAS.
Epigenome‑wide associations study (EWAS) for composite
neonatal morbidity risk score

We then performed an EWAS to identify the average
differences in DNAm for the cumulative increase in the
number of health complications that the infants experienced in the NICU; all models were adjusted for sex,
gestational age, outborn, batch, and proportions of epithelial cells, while PMA (weeks) at buccal collection was
adjusted for the CpGs described above. We identified
ten CpGs that were differentially methylated in association with the neonatal morbidity risk scores after Bonferroni adjustment (Table 2) which will be referred to
as the genome-wide significant CpGs from this point
forward. Additionally, 125 CpGs produced associations within a 10% FDR (Fig. 1 and Additional file 1: Figure S5 and Additional file 2: Excel Table E1); these 125
CpGs were included in all subsequent analyses and
all results for these CpGs are reported in the supplemental materials. Among the genome-wide significant
results, three CpGs were intergenic including the most

statistically significant association (cg09787236 on 6q13;
p value = 3.82E−09), while the other seven CpGs were
annotated to HPS4, SRRD, FGFR1OP, TNS3, TMEM266,
LRRC3B, ZNF780A and TENM2. The only genome-wide
significant CpG that was also identified as a potential
marker of PMA was cg26838315 (10q21.1). This CpG
exhibited the largest magnitude of effect for an increase
in the risk score (β1 = 0.042; p value = 4.64E−08), which
can be interpreted as an average increase in DNAm of
4.2% for each increase in the number of neonatal morbidities, after adjusting for confounders and PMA at buccal swab collection. Interestingly, PMA was associated
with lower levels of DNAm at this CpG (β1 = − 0.007; p
value = 0.00023). Thus, DNAm at cg26838315 is lower
with neonatal aging, while having more neonatal morbidities, which results in an extended length of stay in the
NICU, was associated with increasing levels of DNAm.
We performed a sensitivity analyses to examine whether
additional adjustment for immune cell proportions attenuated our findings for these 10 CpGs and found that
these additional adjustments had no impact on our findings (Additional file 2: Excel Table E2).
We then performed secondary analyses to assess
whether the relationship between DNAm and the neonatal morbidity risk scores was in fact linear or following a
dose–response pattern. Thus, we characterized the average differential methylation associated with each level of
the risk score versus those infants that did not experience
any of BPD, SBI, INF, or ROP, again using linear models
with the same adjustment for covariates but this time
including the risk score as a 4-level factor with a score
of zero as the referent group (Additional file 2: Excel

Table 2 CpG-specific associations between DNAm with a linear increase in composite neonatal morbidity risk score,
adjusted for gestational age at birth (weeks), sex, whether the infant was outborn, the proportion of epithelial cells,
recruitment site, batch, and PMA (weeks) where appropriate; the beta coefficient represents the average difference
in DNA methylation for each increase in the number of morbidities that the infant experienced (BPD, SBI, ROP,
or infection); gene annotations verified in UCSC Genome Browser (hg19)
CpG Site
cg06343740

Coef
0.0111

Std. Err

p value

FDR

Chr

0.0020

2.91E−08

0.0029

chr22

Pos
26878410

Gene

Region

HPS4;SRRD

5′UTR;TSS1500;Body

cg07846767

0.0224

0.0038

4.83E−09

0.0011

chr6

167443722

FGFR1OP

Body

cg08303167

0.0265

0.0048

4.50E−08

0.0033

chr6

126953300

6q22.33

–

cg09787236

0.0278

0.0047

3.82E−09

0.0011

chr6

74652865

6q13

–

cg11255857

0.0187

0.0034

4.08E−08

0.0033

chr7

47431773

TNS3

Body

cg12861771

− 0.0137

cg16636226
cg20938154
cg24517837
cg26838315

0.0254

− 0.0081

0.0024

6.96E−09

0.0012

chr15

76442477

TMEM266

Body

0.0045

1.93E−08

0.0023

chr3

26669219

LRRC3B

5′UTR

0.0014

1.86E−08

0.0023

chr19

40597336

ZNF780A

TSS1500

0.0312

0.0053

4.65E−09

0.0011

chr5

167391645

TENM2

Body

0.0423

0.0077

4.64E−08

0.0033

chr10

59559554

10q21.1

–

CpG cytosine-phosphate-guanine site, Coef. estimated difference in DNAm associated with an increase of one in the neonatal morbidity risk score, Std. Err. standard
error, FDR false discovery rate, Chr. chromosome, Pos. genomic location (hg19)
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Fig. 1 Volcano plot a of the beta coefficients and − log10(p values) from the epigenome-wide association study (EWAS) (blue = FDR < 10%;
red = Bonferroni), and a Manhattan plot b of the genomic distribution of these results with gene names annotated to those CpGs that passed the
Bonferroni threshold

Table E3). We used scatter plots of the magnitudes of differential methylation (reference score = 0) at each CpG
to show that a risk score of 2 produced a greater amount
of differential DNAm, compared to a risk score of 1, for
almost all CpGs; and for most CpGs (72%), a risk score
of 3 + produced greater differential methylation than
the risk score of 2 (Additional file 1: Figure S6). Thus,
the majority of the signal that we observed was predominantly driven by a dose response relationship and
not heavily driven by a single level of the neonatal morbidity risk scores. These dose–response patterns were
also apparent among the ten genome-wide significant
CpGs, although for two of these CpGs (cg09787236 and
cg26838316) the highest level of the risk score (3 +) did
not fit this pattern (Fig. 2).
Identification of differentially methylated regions (DMRs)

We then tested for differentially methylated regions
(DMRs) using DMRff, which performs a modified metaanalysis on the EWAS parameter estimates for differential methylation at the CpGs within candidate regions
that are defined by genomic proximity [42]. We allowed
for a maximum distance of 1500 bp between individually differentially methylated CpGs. Only those individual
CpG sites from the EWAS with a p value < 0.001 were
considered differentially methylated. Using these criteria,
1744 candidate regions were present and 25 DMRs with
at least two differentially methylated CpGs were identified. None of these DMRs exhibited significant regional

differential methylation at the Bonferroni-adjusted
threshold; seven DMRs did produce regional p values
that were equal to or less than the largest p value from
the EWAS that was within an FDR 10% (Table 3).
Differential DNAm associated with individual neonatal
morbidities

We then evaluated whether the observed associations
between DNAm and the cumulative neonatal morbidity risk scores were being driven by any individual health
complication. We regressed DNAm on dichotomous
indicator variables for BPD, SBI, INF, and ROP (all four
included in the model), while adjusting for the same
confounding variables that were included in the EWAS
(Additional file 2: Excel Table E4). We found that DNAm
levels at almost all CpGs were associated (p value < 0.05)
with BPD (89.6%), followed by SBI (45.6%), INF (44.8%),
and ROP (20.0%). Additionally, 23 CpGs were associated
solely with BPD when all four complications were in the
model, while only five, one, and zero CpGs were solely
associated with INF, SBI, and ROP, respectively (Additional file 1: Figure S7). We also found that levels of differential methylation associated with each of the health
complications were highly correlated with the level of differential methylation associated with an increase in one
for the neonatal morbidity risk score (Additional file 1:
Figure S8). These same patterns of association for the
individual health complications were also captured by
the ten genome-wide significant CpGs from our EWAS
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Fig. 2 Partial residual plots of the estimated average DNAm levels (dark grey lines) within each level of the neonatal morbidity risk score, adjusted
for sex, gestational age at birth, outborn, recruitment site, batch, proportions of epithelial cells, and PMA (weeks) were appropriate, for the top 10
CpGs from the EWAS

Table 3 Differentially methylated regions (DMRs) containing at least two CpGs, with an estimated regional change
in DNAm of at least 1% for each increase in the neonatal morbidity risk score and yielding a DMR p value < 0.0001
DMR

# CpGs

Coef

chr2:127822822–127823595

2

chr20:44636682–44636831

2

− 0.0098
0.0119

Std. Err

p value

Gene

Region

0.0019

2.30E−07

BIN1

Body

0.0024

3.86E−07

MMP9

TSS1500

chr12:4489056–4489155

3

0.0145

0.0029

4.16E−07

FGF23

TSS200;TSS1500

chr8:70360215–70361190

5

0.0077

0.0015

5.69E−07

LINC01603

Body;TSS200;TSS1500

− 0.0140

chr13:95358540–95358924

2

chr10:8094142–8094482

3

chr3:142956052–142956059

2

0.0029

1.89E−06

–

–

0.0107

0.0024

1.05E−05

FLJ45983

Body

0.0091

0.0021

1.55E−05

–

–

DMR differentially methylated region, Coef. estimated difference in DNAm associated with an increase of one in the neonatal morbidity risk score, Std. Err. standard
error
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Table 4 CpG-specific associations between DNAm with BPD, SBI, INF and ROP (all were included in the model)
while adjusting for gestational age at birth (weeks), sex, whether the infant was outborn, the proportion of epithelial
cells, recruitment site, batch, and PMA (weeks) where appropriate; the beta coefficient represents the average
difference in DNA methylation for infants that experienced that morbidity in the NICU, relative to those that did not,
while adjusting for the other health complications included in the neonatal morbidity risk score
CpG

Gene

BPD
Coef

SBI
p value

Coef

INF
p value

Coef

ROP
p value

Coef

p value

cg06343740

HPS4;SRRD

0.0111

2.30E−03

0.0098

4.01E−02

0.0131

4.81E−03

0.0083

3.91E−01

cg07846767

FGFR1OP

0.0228

1.03E−03

0.0346

9.64E−05

0.0218

1.03E−02

0.0037

7.88E−01

cg08303167

6q22.33

0.0320

9.73E−04

0.0078

4.96E−01

0.0349

1.24E−03

0.0261

9.39E−02

cg09787236

6q13

0.0320

1.41E−04

0.0315

6.90E−03

0.0296

1.99E−03

0.0012

9.57E−01

cg11255857

TNS3

0.0257

4.15E−05

0.0229

4.97E−03

0.0127

1.08E−01

8.89E−01

3.26E−05

− 0.0118

4.22E−02

− 0.0162

4.89E−04

− 0.0021

0.0332

2.50E−04

0.0414

1.62E−03

− 0.0025

4.37E−01

− 0.0081

8.00E−02

0.0331

4.73E−02

0.0093

6.69E−01

cg12861771

TMEM266

cg16636226

LRRC3B

cg20938154

ZNF780A

cg24517837

TENM2

cg26838315

10q21.1

− 0.0171
0.0235

4.06E−03

− 0.0130

9.11E−07

0.0302

2.97E−03

0.0532

3.00E−04

0.0076

5.11E−01

− 0.0057

9.00E−02

0.0120

3.25E−01

0.0303

3.47E−02

0.0486

3.11E−05

0.0547

1.69E−04

0.0040

7.33E−01

CpG cytosine-phosphate-guanine site, Coef. estimated difference in DNAm associated with the presence of each neonatal morbidities, BPD Bronchopulmonary
dysplasia, INF neonatal infection, SBI serious brain injury, ROP severe retinopathy of prematurity

Fig. 3 Circular bar plots of the estimated average differences in DNAm levels associated with BPD (green), SBI (orange), INF (blue), and ROP (pink),
adjusted for sex, gestational age at birth, outborn, recruitment site, batch, proportions of epithelial cells, and PMA (weeks) where appropriate,
for the top 10 CpGs from the EWAS; all four morbidities were included in the models, and thus, the size of each quadrant represents the relative
magnitude of the difference in DNAm for each morbidity; morbidities that were differentially methylated (p-values < 0.05) while adjusting for all
other morbidities are indicated with an asterisk (*)
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(Table 4 and Fig. 3), with BPD appearing to be the predominant driver of the epigenetic signal from the risk
score. However, it is also important to point out that SBI,
INF, and/or ROP explained differences in DNAm at many
of these CpGs, including all genome-wide significant
CpGs, even when BPD was included in the model. Thus,
the differences in DNAm that we detected are not merely
capturing the effects of BPD, but instead may be reflecting a more integrated marker of neonatal health.
Over‑representation of genes in biological pathways

We explored the biological activities of the gene sets that
were most strongly associated with the neonatal morbidity risk scores. None of the identified pathways were
significantly enriched after adjustment for multiple testing and only three pathways were enriched at a significance level of p value < 0.10, including Cushing syndrome
(hsa:04934), Wnt signaling pathway (hsa:04310), and
Oxytocin signaling pathway (hsa:04921). We considered
that our gene set, which only included 125 CpGs, may be
underpowered to detect enrichment and thus relaxed the
significance threshold to FDR levels of 15% (243 CpGs),
20% (375 CpGs), and 25% (549 CpGs) and then reran the
enrichment analyses. Only one pathway was nominally
enriched for (p value < 0.05) in all three of these analyses, the Wnt signaling pathway (hsa:04,310) from which
our CpGs included 7 genes (p value = 0.049), 9 genes (p
value = 0.0032), and 11 genes (p value = 0.0049) for the
FDR cutoffs of 15%, 20%, and 25%, respectively. However,
again, none of these p values were statistically significant
after adjusting for multiple testing.
Summary of results

In summary, cumulative neonatal morbidities were
strongly associated with increasing DNAm at eight
CpGs and decreasing DNAm at two CpGs (α adjusted
for 706,278 tests). These relationships were largely linear and followed dose–response patterns, demonstrating
the robustness of these associations. Additionally, nine
of these ten CpGs were associated with more than one
neonatal health complication, when all complications
were included as dichotomous variables within the same
model. Thus, the differences in DNAm that we detected
were not being driven by any single complication, but
instead may represent a more integrated marker of prematurity or neonatal health.

Discussion
In a cohort of infants that were born very preterm
(< 30 weeks gestation), we identified a DNAm signature
associated with increasing numbers of neonatal morbidities at specific CpG sites in three intergenic regions
on 6q22.33, 6q13, and 10q21.1, and within the genes,
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HPS4, SRRD, FGFR1OP, TNS3, TMEM266, LRRC3B,
ZNF780A, and TENM2. Additionally, we observed evidence of regional differences in DNAm at BIN1, MMP9,
FGF23, LINC01603, FLJ45983 and two intergenic
regions, although these regional differences did not meet
the Bonferroni-adjusted significance threshold. Among
the four complications included in the neonatal morbidity risk score, BPD appeared to be the primary driver of
the epigenetic responses. However, SBI, INF, and/or ROP
were associated with differential methylation at all of the
genome-wide significant CpG sites in addition to BPD.
Thus, these epigenetic differences may be related to common processes that either contribute to, or are affected
by, these severe neonatal health complications.
Among these 13 genes, some common biological processes were represented. For instance two CpG sites were
within genes, TNS3 and FGFR1OP, that can interact with
and potentially influence the function of the fibroblast
growth factor receptor (FGFR), and which has previously
been observed in cases of developmental disorder and
myeloproliferative disorder, respectively [44, 45]. One
DMR was within FGF23, which has pleiotropic effects
on multiple processes, including metabolism of phosphate, calcium and sodium, bone mineralization [46, 47].
FGF23 does appear to be highly expressed in the neonatal period [48, 49], and as a family, FGFs have extensive
roles during embryonic development in processes related
to organogenesis, such as proliferation and differentiation [50]. Additionally, FGFs are significant angiogenic
factors [51, 52] and dysregulation of angiogenic processes
are thought to contribute to the development of some
of these neonatal health complications [5]. LRRC3B and
MMP9 have been associated with mechanisms of cellular
proliferation, invasion, and cell cycle regulation [53, 54],
and interestingly, LRRC3B has been shown to inhibit the
expression of MMP9 in one study [55]. TMEM266 produces a functional voltage sensor at synapses in the cerebellum and thus may play important roles of neuronal
signaling [56, 57] while TENM2 appears to be involved
in neuronal growth and migration [58]. BIN1 has been
associated with neurodegenerative diseases [59] and may
be involved in neuronal function [60]. The potential roles
that these genes play in the neonatal period are not well
described, and it is not clear if buccal cell DNAm patterns
at these genes are reflective of DNAm patterns at these
same genes in neuronal, respiratory, and immune cells.
However, our data suggest that cellular process related to
fibroblast growth factor activities, cellular proliferation
and invasion, and neural development and signaling may
be sensitive to severe neonatal morbidities in infants that
are born very preterm.
While our study focused on epigenetic variation
that is associated with the burden of multiple neonatal
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morbidities in very preterm infants, other studies have
previously shown that preterm birth itself is associated with differential DNAm in several different tissues,
including placenta [61], neonatal blood [9–11], and neonatal saliva [37]. Many of the CpG sites that have been
associated with preterm birth in these prior studies are
within genes that are involved in neuronal development
and/or neurodegenerative disorders, and we have previously found that neonatal neurobehavioral responses
in preterm infants are associated with differences in
DNAm [30]. Furthermore, some of the CpGs associated
with preterm birth have been shown to be differentially
methylated in adult blood, suggesting that DNAm could
potentially mediate some of the long-term health consequences that are associated with prematurity [9, 12].
Our findings provide supporting evidence that neonatal
DNAm in preterm infants may inform future health outcomes by identifying epigenetic variation associated with
neonatal morbidities, BPD, SBI, INF, and ROP, which are
predictive of persistent developmental impairments [1,
3].
In summary, we identified a robust epigenetic signature
of neonatal health complications at a genome-wide significance threshold that exhibited dose response relationships with the neonatal morbidity risk score and occurred
within genes whose epigenetic dysregulation could plausibly be related to future developmental outcomes. However, we also want to stress some of the limitations of this
analysis, including potential residual confounding, lack
of independent replication and lack of access to ideal target tissues. There is likely measurement error for some
of our different age metrics (gestational age and PMA),
since the date of conception was estimated using the best
information available, but gold standard assessments
were not available for many of our newborns; thus, there
may be some residual confounding from these age metrics. Due to the uniqueness of our sample of very preterm
infants (< 30 weeks of gestation), we are not aware of an
independent population with neonatal buccal cell DNAm
data within which to perform a replications analysis.
Additionally, although DNAm was measured in a peripheral tissue, target tissues related to these health complications are mostly inaccessible for observational studies of
living children. Buccal cells, on the other hand, are one
of the most accessible tissues for studies of children [62]
and have been suggested to be one of the preferred surrogate tissues for epigenetic studies of psychiatric and
neurobehavioral outcomes [63–65]. It is possible that
the observed differences in DNAm could be correlated
with relevant biological process affected by prematurity
or represent surrogate indicator of prematurity and thus
may be predictive of future health consequences even
if they are not causally involved in those pathological
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processes. Additionally, we used a cumulative risk index
to assess the impact of multiple neonatal morbidities,
rather than performing separate EWAS analyses of each
morbidity independently. This approach reduced the
multiple testing burden that would have been necessary
for testing each morbidity separately. However, by focusing on this risk index, we likely did not capture all of the
epigenetic responses that may be related to these specific morbidities. Future studies could test for differential
DNAm associated specifically with SBI, BPD, ROP, and
neonatal infections, or with other impairments that were
not included in our analyses. Despite these limitations,
our results provide evidence regarding the impact of
neonatal morbidities among very preterm infants on the
early-life epigenome and provide promising candidates
for future studies of epigenetic predictors of neurodevelopmental impairment.
We observed differences of 1–4% methylation, for
each unit increase in morbidity risk score, and when
comparing those with 3 + morbidities to those with no
morbidities, the largest differences were around 9% (at
cg26838315 and cg24517837). These effect sizes, while
small on the absolute scale, are consistent with what is
observed in other epidemiologic studies of DNA methylation and children’s health [66]. We should be cautious
in interpreting small differences in DNA methylation
and the potential functional consequences of those differences. However, it is important to emphasize that our
study, and most epidemiologic studies, measures DNA
methylation from tissue samples that are composed of
many cells. Thus, for a given CpG site, the beta-value
(percent DNAm) represents the proportion of alleles,
across many cells, where that CpG was methylated. However, within an individual cell, a CpG is either methylated
or unmethylated. Thus, a “small” difference in percent
DNAm at a particular CpG is likely representative of a
subpopulation of cells with a different methylation state
at that genomic location. Because DNAm can be inherited across cellular divisions, these differences may be
representative of prior exposures or events and they may
persist with growth and aging. Important future research
should investigate whether these differences in DNAm
persist, amplify, or attenuate as these children age, and
whether these dynamics are related to differences in
neurodevelopmental impairments. We aim to investigate such DNAm dynamics in relation to these outcomes
with future studies in this ongoing longitudinal cohort of
babies that were born very preterm.

Conclusions
In summary, the serious neonatal morbidities experienced by infants that are born very preterm appear to
leave a signature on the epigenome at the time that those
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infants are discharged from the NICU. While BPD was
the most substantial driver of this epigenetic signature, all
of these health complications of prematurity contributed
to the observed differential methylation. Additionally,
these epigenetic variations occur within genes involved
in developmental processes. Thus, we hypothesize that
these epigenetic features may be representative of an
integrated marker of neonatal health and development
and should be considered as potential candidates for
future studies of developmental impairments in children
who were born premature. Our ongoing work in NOVI
aims to examine whether these differences in DNAm
persist with aging and to integrate these epigenetic data
with clinical information to test whether the inclusion of
epigenetic information can improve predictions about
neurodevelopmental impairments in childhood.
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